TSANZ home

Results for "approved lab"

Home 5 Search query for: approved lab
Results for "approved lab"
VOLUME 6.05 – JULY 2021

VOLUME 6.05 – JULY 2021

Research Roundup:

May 2021

Welcome Message

Welcome to another edition of our TSANZ Research Roundup. It was fantastic to see so many people tune-in to our first ever virtual conference earlier this month. I would like to offer a huge congratulations to everyone who has continued to champion respiratory research by adapting approaches and pushing through despite the COVID-19 pandemic. The presentations on display were testimony to our society of dedicated and steadfast professionals.

I am honoured to be taking over as Chair of the Research Sub-Committee from Professor Sandy Hodge, who has done a brilliant job of leading our collective interests over the past four years. If there is anything the committee or I can do to help support your research activities, please do not hesitate to get in touch.

We are please to announce that over $300,000 has been awarded for respiratory research excellence in 2021. Huge congratulations to all the award recipients and good luck with your research. Two awards are currently open, being a TSANZ and National Asthma Council Australia Career Development Fellowship and a NZ Branch travel grant closing 31st of May and 8th of August respectively. There is an Asthma Australia Research Grant and Workshop on offer later this month and calls for applicants in the 2021 Australian Museum Eureka Prizes are open until the 28th of May.

Check out The Limbic, Respirology Editor’s Choice and Respiratory Research Review segments for a snapshot of some great respiratory research going on. Finally, if you have an interest in lung cancer care, acute exacerbations of COPD or helping to inform the top 10 research priorities for pulmonary fibrosis, click on the survey links below.

Enjoy the May edition of your Research Roundup.

A/Prof Kristin Carson-Chahhoud
Chair, Research Sub-Committee 

2021 RESPIRATORY RESEARCH EXCELLENCE AWARD WINNERS

$300,000 FOR LUNG DISEASE RESEARCH ANNOUNCED

(Saturday, 1st May 2021): Over $300,000 in lung research investment was announced this weekend at the Respiratory Research Excellence Awards, presented in a virtual format alongside the Australia and New Zealand Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science (TSANZSRS 2021).

This prestigious selection of awards are presented to TSANZ members who are at various stages of their career and doing outstanding work. These awards aim to support individuals through project funding, fellowships and travel grants.

“This funding enables our researchers to learn more and develop their skills, with the overall goal of preventing, curing and alleviating disability from lung disease. Every dollar invested takes us one step closer to reaching that goal,” said TSANZ President Elect Professor John Upham.

“We’re honoured to be able to support some of Australia’s most innovative researchers working on lung disease and lung health. This research will make a difference to the lives of the 1 in 4 Australians with lung disease,” he said.

Thoracic Society of Australia and New Zealand (TSANZ) – the hosts of TSANZSRS – are pleased to announce awards from Cystic Fibrosis Australia, the National Asthma Council Australia, Lung Foundation Australia and the Centre of Research Excellence in Pulmonary Fibrosis.

“The TSANZ is privileged to support a diverse awards program that recognises the best and brightest minds in respiratory health that will shape the lung health of our communities into the future” said TSANZ CEO, Dr Graham Hall.

The research awards are supported by the generosity of private donations, sponsorship and leveraged financing from recipients’ institutions. Thank you to our generous sponsors and organisational partners for enabling our world-class researchers to continue to create respiratory knowledge and build capacity in the respiratory workforce, with the overall goal to prevent, cure and relieve disability from lung disease.

2021 RESPIRATORY RESEARCH EXCELLENCE AWARD WINNERS

TSANZ would like to congratulate the following Award winners.

TSANZ Janet Elder Travel Award – Early  Career – Maggie Lam, Monash University

TSANZ Janet Elder Travel Award – Early Career – Melissa Preissner, Monash University

TSANZ Janet Elder Travel Award – Early Career – Mariana Hoffman Barbosa, Monash University

BI NZ Primary Care Grant – Sarah Mooney, Auckland University of Technology

Past President’s Scholarship Award – Elena Schneider-Futschik, The University of Melbourne

TSANZ Peter Phelan Research Award – Thomas Iosifidis, Curtin University and Telethon Kids Institute

TSANZ/Maurice Blackburn GIA – Keshav Raj Paudel, University of Technology Sydney

TSANZ Robert Pierce GIA for ILH – Peter Wark, University of Newcastle and Hunter Medical Research Institute

Ann Woolcock New Investigator Award – Nicole Sheers, Austin Health, University of Melbourne

CREATE Grant-in-Aid For new collaborative research between CREATE Fellows (CRE-PF and Lung Foundation Australia) – Gang Liu, Ashleigh Philp & Laura Glenn, UTS, UNSW & The University of Sydney

CREATE Grant-in-Aid For new collaborative research between CREATE Fellows (CRE-PF and Lung Foundation Australia) – Laura Glenn, Alan Teoh, Hayley Barnes & John Mackintosh, RPAH, Alfred Health & Prince Charles Hospital

PACT Grant-in-Aid For Investigator Led Pulmonary Fibrosis Clinical Research (Lung Foundation Australia and CRE-PF) – Yet Hong Khor & Christopher Ryerson, Austin Health & University of British Columbia

CREATE Hope PhD Scholarships in Pulmonary Fibrosis (Lung Foundation Australia and CRE-PF) -Joanna Lee, Monash University

CREATE Hope PhD Scholarships in Pulmonary Fibrosis (Lung Foundation Australia and CRE-PF) -Claudia Sim, Monash University

Open Awards

Thoracic Society Awards

TSANZ and National Asthma Council Australia Asthma and Airways Career Development Fellowship – closing 31 May 2021

TSANZ NZ Branch ASM 2021 Travel Grant – closing 8 August 2021

Asthma Australia Research Grant and Workshop

Asthma Australia would like to invite you to a workshop which aims to share ideas and invoke research partnerships around issues relevant to people disproportionately affected by asthma. At the end of the meeting, Asthma Australia will re-announce a $300,000 Strategic Alliance grant for such work.

At Asthma Australia, we are committed to doing things differently in our quest to help people live freely from their disease and hope you are ready to join us. Thanks to the Ray O’Donnell Belgrave Lions Asthma Research Fund, we are seeking to fund research from Victorian-led research collaborations to answer the evidence gaps and develop solutions for people from the three following population segments disproportionately affected by asthma:

  • Aboriginal and Torres Strait Islander People
  • People facing socioeconomic disadvantage
  • People from culturally and linguistically diverse backgrounds.

We will be holding one workshop (up to 90 minutes) for each population segment and want you to attend.

At the workshops you will hear why this research funding is a priority in Australia for people with asthma. We will facilitate a discussion among participants about why these inequities persist and share ideas around potential collaborations and novel approaches that aim to address them. After the workshops, applications will open to apply for the $300,000 Strategic Alliance Grant. 

    Workshop  details

    1. Culturally and linguistically diverse backgrounds

    When: Wednesday 26th May 11-12:30
    Where: Ethnic Community Council Victoria

    1. People facing socioeconomic disadvantage
      Tuesday 25th May 2-3:30pm
    1. Aboriginal and Torres Strait Islander People
      TBC – please register interest

    If you are interested in applying for this grant, please contact Asthma Australia (via research@asthma.org.auwith your name, organisation and the workshop you would like to attend.  

    2021 Australian Museum Eureka Prizes

    Do you know someone making a difference in their field?

    Entries to the 2021 Australian Museum Eureka Prizes are now open!

    This year, there are 16 prizes on offer that cover a broad spectrum of scientific disciplines, which aim to recognise the achievements of scientists, researchers, and science communicators at all career stages.

    There are prizes available for both individuals and teams, and entrants can either enter themselves or be nominated. The Eureka Prizes are open, but not limited to, those who work in research institutes, government departments, media, corporations, and universities. It’s free to enter and there’s a prize pool of $160,000 to be shared between the winners.

    If you know an individual or team doing outstanding work, why not encourage them to enter?

    Entries close 7pm AEST Friday 28 May

    VIEW THE FULL PRIZE PROGRAM

    Respirology – Editor’s Choice

    Respirology Issue 26.4 April 2021

    Central airway collapse is related to obesity independent of asthma phenotype

    Swati A. Bhatawadekar, Ubong Peters, Ryan R. Walsh, Nirav Daphtary, Erick S. Maclean, Vitor Mori, Kevin Hodgdon, C. Matthew Kinsey, David A. Kaminsky, Jason H.T. Bates and Anne E. Dixon

    DOI: 10.1111/resp.14005

    Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis‐associated ILD: A randomized, open‐label trial

    Tomoyuki Fujisawa, Hironao Hozumi, Yosuke Kamiya, Yusuke Kaida, Taisuke Akamatsu, Hideki Kusagaya, Yasuomi Satake, Kazutaka Mori, Masashi Mikamo, Hiroyuki Matsuda, Koshi Yokomura, Naoki Koshimizu, Mikio Toyoshima, Shiro Imokawa, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui, and Takafumi Suda

    DOI: 10.1111/resp.13978

    Surveys and Research

    SURVEY OF LUNG CANCER CARE IN AUSTRALIA

    We would be grateful please for less than 5 minutes of your time to complete this survey which is designed to provide a snapshot of the current status of lung cancer care and MDTs around Australia.

    • These data will help inform vital services planning for lung cancer care and will directly inform ongoing discussions with Government about lung cancer care across Australia.
    • We are only asking for one response from each institution, we suggest it is the lead clinician for the lung cancer MDT.
    • Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number HRE2021-0031).

    Please follow the link to the Australian-wide Survey of Lung Cancer Care, or use the QR code below.

    Thank you for your time.

    Prof Fraser Brims
    Curtin Medical School
    fraser.brims@curtin.edu.au 

    GP PARTICIPATION REQUIRED

    Investigators from Monash University are conducting a RACGP-funded national survey of GPs regarding the management of patients with acute exacerbations of COPD.

    Acute exacerbations of COPD are a leading cause of hospitalisation, with a substantial proportion of cases being potentially preventable. We are seeking GPs to complete a short survey that aims to better understand current practice and unmet needs in order to optimise care for these patients. Due to the current COVID-19 vaccination rollout across Australia, it is very challenging to secure participation. Any assistance to distribute this among your contacts is greatly appreciated.

    All eligible participants who complete the survey will have the chance to win one of two $250 gift vouchers, and anyone who completes an optional follow-up qualitative interview will receive a $250 gift voucher.

    The survey can be accessed by clicking HERE.

    The survey has been approved by the Monash University Human Research Ethics Committee (MUHREC ref. 26571). If you have any queries, please contact Dr Bianca Perera at bianca.perera@monash.edu, Dr. Chris Barton at chris.barton@monash.edu or Dr Christian Osadnik (Principal investigator) at christian.osadnik@monash.edu.

     

    TOP 10 RESEARCH PRIORITIES FOR PULMONARY FIBROSIS

    A recent research study as part of the NHMRC’s Centre of Research Excellence in Pulmonary Fibrosis grant aimed to identify the top 10 research priorities for pulmonary fibrosis (PF) according to people living with pulmonary fibrosis, caregivers, health professionals and researchers.

    This study has now been completed and below is a summary of the findings from this work.

    The top 3 priorities rank by people with PF and caregivers were:

    1. What medications can reverse scarring in the lungs of people with PF?
    2. What medications can improve lung function in people with PF?
    3. What are the causes of PF?

    The top 3 priorities rank by people with healthcare professionals/researchers were:

    1. What medications can reverse scarring in the lungs of people with PF?
    2. How can we prevent PF?
    3. What are the causes of PF?

    The findings from this study have been published in a peer-reviewed journal and will help guide future research directions.

    (click on the link to view the paper– https://doi.org/10.1136/thoraxjnl-2020-215731)

    The Study team extends their thanks and appreciation to all those who participated in the study for their time and valuable contribution to this work.

    Yours sincerely,

    Anne Holland
    Professor of Physiotherapy (Research), Monash University (anne.holland@monash.edu)

    TBPod

    The TBPod are podcasts designed for clinicians and policymakers with an interest tuberculosis. These podcasts consist of conversations with expert clinicians, researchers, policy makers and advocates about their work in the field of tuberculosis. The TBPod is prepared by ACTnet and the TB Forum and can be found on ITunes, Spotify, and the ACTnet Website.

    Can you help TSANZ make a difference?

    Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

    1. Making a donation to our Benevolent Fund

    The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
    CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

    2. Making a donation to support research

    With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
    Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

    3. Establishing a named award

    For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

    4. Leave TSANZ a gift in your will

    If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
    If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

    5. TSANZ New Zealand Branch Incorporated 

    New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt.
    CLICK HERE to make a donation.

    Thank you for your continued support of TSANZ.

    VOLUME 6.05 – JULY 2021

    VOLUME 6.04 – MAY 2021

    Research Roundup:

    May 2021

    Welcome Message

    Welcome to another edition of our TSANZ Research Roundup. It was fantastic to see so many people tune-in to our first ever virtual conference earlier this month. I would like to offer a huge congratulations to everyone who has continued to champion respiratory research by adapting approaches and pushing through despite the COVID-19 pandemic. The presentations on display were testimony to our society of dedicated and steadfast professionals.

    I am honoured to be taking over as Chair of the Research Sub-Committee from Professor Sandy Hodge, who has done a brilliant job of leading our collective interests over the past four years. If there is anything the committee or I can do to help support your research activities, please do not hesitate to get in touch.

    We are please to announce that over $300,000 has been awarded for respiratory research excellence in 2021. Huge congratulations to all the award recipients and good luck with your research. Two awards are currently open, being a TSANZ and National Asthma Council Australia Career Development Fellowship and a NZ Branch travel grant closing 31st of May and 8th of August respectively. There is an Asthma Australia Research Grant and Workshop on offer later this month and calls for applicants in the 2021 Australian Museum Eureka Prizes are open until the 28th of May.

    Check out The Limbic, Respirology Editor’s Choice and Respiratory Research Review segments for a snapshot of some great respiratory research going on. Finally, if you have an interest in lung cancer care, acute exacerbations of COPD or helping to inform the top 10 research priorities for pulmonary fibrosis, click on the survey links below.

    Enjoy the May edition of your Research Roundup.

    A/Prof Kristin Carson-Chahhoud
    Chair, Research Sub-Committee 

    2021 RESPIRATORY RESEARCH EXCELLENCE AWARD WINNERS

    $300,000 FOR LUNG DISEASE RESEARCH ANNOUNCED

    (Saturday, 1st May 2021): Over $300,000 in lung research investment was announced this weekend at the Respiratory Research Excellence Awards, presented in a virtual format alongside the Australia and New Zealand Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science (TSANZSRS 2021).

    This prestigious selection of awards are presented to TSANZ members who are at various stages of their career and doing outstanding work. These awards aim to support individuals through project funding, fellowships and travel grants.

    “This funding enables our researchers to learn more and develop their skills, with the overall goal of preventing, curing and alleviating disability from lung disease. Every dollar invested takes us one step closer to reaching that goal,” said TSANZ President Elect Professor John Upham.

    “We’re honoured to be able to support some of Australia’s most innovative researchers working on lung disease and lung health. This research will make a difference to the lives of the 1 in 4 Australians with lung disease,” he said.

    Thoracic Society of Australia and New Zealand (TSANZ) – the hosts of TSANZSRS – are pleased to announce awards from Cystic Fibrosis Australia, the National Asthma Council Australia, Lung Foundation Australia and the Centre of Research Excellence in Pulmonary Fibrosis.

    “The TSANZ is privileged to support a diverse awards program that recognises the best and brightest minds in respiratory health that will shape the lung health of our communities into the future” said TSANZ CEO, Dr Graham Hall.

    The research awards are supported by the generosity of private donations, sponsorship and leveraged financing from recipients’ institutions. Thank you to our generous sponsors and organisational partners for enabling our world-class researchers to continue to create respiratory knowledge and build capacity in the respiratory workforce, with the overall goal to prevent, cure and relieve disability from lung disease.

    2021 RESPIRATORY RESEARCH EXCELLENCE AWARD WINNERS

    TSANZ would like to congratulate the following Award winners.

    TSANZ Janet Elder Travel Award – Early  Career – Maggie Lam, Monash University

    TSANZ Janet Elder Travel Award – Early Career – Melissa Preissner, Monash University

    TSANZ Janet Elder Travel Award – Early Career – Mariana Hoffman Barbosa, Monash University

    BI NZ Primary Care Grant – Sarah Mooney, Auckland University of Technology

    Past President’s Scholarship Award – Elena Schneider-Futschik, The University of Melbourne

    TSANZ Peter Phelan Research Award – Thomas Iosifidis, Curtin University and Telethon Kids Institute

    TSANZ/Maurice Blackburn GIA – Keshav Raj Paudel, University of Technology Sydney

    TSANZ Robert Pierce GIA for ILH – Peter Wark, University of Newcastle and Hunter Medical Research Institute

    Ann Woolcock New Investigator Award – Nicole Sheers, Austin Health, University of Melbourne

    CREATE Grant-in-Aid For new collaborative research between CREATE Fellows (CRE-PF and Lung Foundation Australia) – Gang Liu, Ashleigh Philp & Laura Glenn, UTS, UNSW & The University of Sydney

    CREATE Grant-in-Aid For new collaborative research between CREATE Fellows (CRE-PF and Lung Foundation Australia) – Laura Glenn, Alan Teoh, Hayley Barnes & John Mackintosh, RPAH, Alfred Health & Prince Charles Hospital

    PACT Grant-in-Aid For Investigator Led Pulmonary Fibrosis Clinical Research (Lung Foundation Australia and CRE-PF) – Yet Hong Khor & Christopher Ryerson, Austin Health & University of British Columbia

    CREATE Hope PhD Scholarships in Pulmonary Fibrosis (Lung Foundation Australia and CRE-PF) -Joanna Lee, Monash University

    CREATE Hope PhD Scholarships in Pulmonary Fibrosis (Lung Foundation Australia and CRE-PF) -Claudia Sim, Monash University

    Open Awards

    Thoracic Society Awards

    TSANZ and National Asthma Council Australia Asthma and Airways Career Development Fellowship – closing 31 May 2021

    TSANZ NZ Branch ASM 2021 Travel Grant – closing 8 August 2021

    Asthma Australia Research Grant and Workshop

    Asthma Australia would like to invite you to a workshop which aims to share ideas and invoke research partnerships around issues relevant to people disproportionately affected by asthma. At the end of the meeting, Asthma Australia will re-announce a $300,000 Strategic Alliance grant for such work.

    At Asthma Australia, we are committed to doing things differently in our quest to help people live freely from their disease and hope you are ready to join us. Thanks to the Ray O’Donnell Belgrave Lions Asthma Research Fund, we are seeking to fund research from Victorian-led research collaborations to answer the evidence gaps and develop solutions for people from the three following population segments disproportionately affected by asthma:

    • Aboriginal and Torres Strait Islander People
    • People facing socioeconomic disadvantage
    • People from culturally and linguistically diverse backgrounds.

    We will be holding one workshop (up to 90 minutes) for each population segment and want you to attend.

    At the workshops you will hear why this research funding is a priority in Australia for people with asthma. We will facilitate a discussion among participants about why these inequities persist and share ideas around potential collaborations and novel approaches that aim to address them. After the workshops, applications will open to apply for the $300,000 Strategic Alliance Grant. 

      Workshop  details

      1. Culturally and linguistically diverse backgrounds

      When: Wednesday 26th May 11-12:30
      Where: Ethnic Community Council Victoria

      1. People facing socioeconomic disadvantage
        Tuesday 25th May 2-3:30pm
      1. Aboriginal and Torres Strait Islander People
        TBC – please register interest

      If you are interested in applying for this grant, please contact Asthma Australia (via research@asthma.org.auwith your name, organisation and the workshop you would like to attend.  

      2021 Australian Museum Eureka Prizes

      Do you know someone making a difference in their field?

      Entries to the 2021 Australian Museum Eureka Prizes are now open!

      This year, there are 16 prizes on offer that cover a broad spectrum of scientific disciplines, which aim to recognise the achievements of scientists, researchers, and science communicators at all career stages.

      There are prizes available for both individuals and teams, and entrants can either enter themselves or be nominated. The Eureka Prizes are open, but not limited to, those who work in research institutes, government departments, media, corporations, and universities. It’s free to enter and there’s a prize pool of $160,000 to be shared between the winners.

      If you know an individual or team doing outstanding work, why not encourage them to enter?

      Entries close 7pm AEST Friday 28 May

      VIEW THE FULL PRIZE PROGRAM

      Respirology – Editor’s Choice

      Respirology Issue 26.4 April 2021

      Central airway collapse is related to obesity independent of asthma phenotype

      Swati A. Bhatawadekar, Ubong Peters, Ryan R. Walsh, Nirav Daphtary, Erick S. Maclean, Vitor Mori, Kevin Hodgdon, C. Matthew Kinsey, David A. Kaminsky, Jason H.T. Bates and Anne E. Dixon

      DOI: 10.1111/resp.14005

      Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis‐associated ILD: A randomized, open‐label trial

      Tomoyuki Fujisawa, Hironao Hozumi, Yosuke Kamiya, Yusuke Kaida, Taisuke Akamatsu, Hideki Kusagaya, Yasuomi Satake, Kazutaka Mori, Masashi Mikamo, Hiroyuki Matsuda, Koshi Yokomura, Naoki Koshimizu, Mikio Toyoshima, Shiro Imokawa, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui, and Takafumi Suda

      DOI: 10.1111/resp.13978

      Surveys and Research

      SURVEY OF LUNG CANCER CARE IN AUSTRALIA

      We would be grateful please for less than 5 minutes of your time to complete this survey which is designed to provide a snapshot of the current status of lung cancer care and MDTs around Australia.

      • These data will help inform vital services planning for lung cancer care and will directly inform ongoing discussions with Government about lung cancer care across Australia.
      • We are only asking for one response from each institution, we suggest it is the lead clinician for the lung cancer MDT.
      • Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number HRE2021-0031).

      Please follow the link to the Australian-wide Survey of Lung Cancer Care, or use the QR code below.

      Thank you for your time.

      Prof Fraser Brims
      Curtin Medical School
      fraser.brims@curtin.edu.au 

      GP PARTICIPATION REQUIRED

      Investigators from Monash University are conducting a RACGP-funded national survey of GPs regarding the management of patients with acute exacerbations of COPD.

      Acute exacerbations of COPD are a leading cause of hospitalisation, with a substantial proportion of cases being potentially preventable. We are seeking GPs to complete a short survey that aims to better understand current practice and unmet needs in order to optimise care for these patients. Due to the current COVID-19 vaccination rollout across Australia, it is very challenging to secure participation. Any assistance to distribute this among your contacts is greatly appreciated.

      All eligible participants who complete the survey will have the chance to win one of two $250 gift vouchers, and anyone who completes an optional follow-up qualitative interview will receive a $250 gift voucher.

      The survey can be accessed by clicking HERE.

      The survey has been approved by the Monash University Human Research Ethics Committee (MUHREC ref. 26571). If you have any queries, please contact Dr Bianca Perera at bianca.perera@monash.edu, Dr. Chris Barton at chris.barton@monash.edu or Dr Christian Osadnik (Principal investigator) at christian.osadnik@monash.edu.

       

      TOP 10 RESEARCH PRIORITIES FOR PULMONARY FIBROSIS

      A recent research study as part of the NHMRC’s Centre of Research Excellence in Pulmonary Fibrosis grant aimed to identify the top 10 research priorities for pulmonary fibrosis (PF) according to people living with pulmonary fibrosis, caregivers, health professionals and researchers.

      This study has now been completed and below is a summary of the findings from this work.

      The top 3 priorities rank by people with PF and caregivers were:

      1. What medications can reverse scarring in the lungs of people with PF?
      2. What medications can improve lung function in people with PF?
      3. What are the causes of PF?

      The top 3 priorities rank by people with healthcare professionals/researchers were:

      1. What medications can reverse scarring in the lungs of people with PF?
      2. How can we prevent PF?
      3. What are the causes of PF?

      The findings from this study have been published in a peer-reviewed journal and will help guide future research directions.

      (click on the link to view the paper– https://doi.org/10.1136/thoraxjnl-2020-215731)

      The Study team extends their thanks and appreciation to all those who participated in the study for their time and valuable contribution to this work.

      Yours sincerely,

      Anne Holland
      Professor of Physiotherapy (Research), Monash University (anne.holland@monash.edu)

      TBPod

      The TBPod are podcasts designed for clinicians and policymakers with an interest tuberculosis. These podcasts consist of conversations with expert clinicians, researchers, policy makers and advocates about their work in the field of tuberculosis. The TBPod is prepared by ACTnet and the TB Forum and can be found on ITunes, Spotify, and the ACTnet Website.

      Can you help TSANZ make a difference?

      Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

      1. Making a donation to our Benevolent Fund

      The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
      CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      2. Making a donation to support research

      With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
      Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      3. Establishing a named award

      For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

      4. Leave TSANZ a gift in your will

      If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
      If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

      5. TSANZ New Zealand Branch Incorporated 

      New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt.
      CLICK HERE to make a donation.

      Thank you for your continued support of TSANZ.

      New drugs for pulmonary fibrosis – are there any blockbusters around the corner?

      New drugs for pulmonary fibrosis – are there any blockbusters around the corner?

      Date Recorded: 30th March 2021

      This webinar will catch health professionals up on the latest in drug development and clinical trials in pulmonary fibrosis.

      It is so heartening to be able to speak optimistically about the future when we see our patients with IPF and other interstitial lung disease in the clinic. Not only do we have two approved drugs, but there are multiple potential breakthrough treatments in clinical development right now, many of them in late phase clinical trials.

      Presenters and topics:

      • Prof Glen Westall – “Current thoughts on pathogenesis of IPF and potential pathways of therapeutic target”
      • Prof Dan Chambers – “Current and upcoming clinical trials”
        The presenters:

      Prof Glen Westall is a Consultant Chest Physician, and Head of the Paediatric Lung Transplant Program at the Alfred Hospital, Melbourne. He trained at King’s College London, and completed his respiratory training at the Alfred Hospital, Melbourne and Royal Brompton Hospital, London. Glen is a lead Consultant in Melbourne’s largest dedicated Lung Fibrosis service that operates within the Department of Respiratory Medicine at the Alfred Hospital.

      Prof Dan Chambers is a thoracic and transplant physician with special interests in immunology and interstitial lung disease. After graduating from The University of Queensland (1993, University Medal) he trained in thoracic medicine and transplantation and completed an MD. Dan is now Director of the World Lung and Heart-lung Transplant Registry – the first Australian to hold that position.

      In collaboration with:
      The Centre for Research Excellence in Pulmonary Fibrosis & Pulmonary Fibrosis Australasian Clinical Trials (PACT) Network

      Registration:

      To register your interest in the on-demand recording, please register below. You will then be sent an e-mail, allowing you to obtain the recording links through Vimeo.

      Category Fee (excl. GST)
      TSANZ Members Free
      Non-members Free

      Require assistance?

      Please contact the TSANZ Office on +61 2 9222 6200 or e-mail tsanzeducation@thoracic.org.au

      VOLUME 6.05 – JULY 2021

      VOLUME 6.03 – MARCH 2021

      Research Roundup:

      March 2021

      Welcome Message

      We hope you’ve been keeping safe and well.

      The TSANZ and National Asthma Council Australia Asthma and Airways Career Development Fellowship is now open. This award aims to facilitate the establishment of mid-career invenstigators as independent, self-directed researchers and to foster the development of high-quality respiratory research in Australia and New Zealand.

      Please note that the TSANZ Indigenous Respiratory Nursing Award will be closing 12 April 2021 and the Boehringer Ingelheim New Zealand Primary Care Award will be closing 05 April 2021.

       

      Don’t forget to register for our first ever Virtual Annual Scientific Meeting – TSANZSRS21.

      Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below.

      Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

      Enjoy the March edition of your Research Roundup.

      Prof Sandra Hodge

      Chair, Research Sub-Committee

      Open Awards

      Thoracic Society Awards

      TSANZ Indigenous Respiratory Nursing Award – extended – closing 12 April 2021

      Boehringer Ingelheim New Zealand Primary Care Award – closing 05 April 2021

      TSANZ and National Asthma Council Australia Asthma and Airways Career Development Fellowship – closing 31 May 2021

        

      How to participate

      Follow the links above to access each award application form and download the information sheet.

      Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

      2021 Australian Museum Eureka Prizes

      Do you know someone making a difference in their field?

      Entries to the 2021 Australian Museum Eureka Prizes are now open!

      This year, there are 16 prizes on offer that cover a broad spectrum of scientific disciplines, which aim to recognise the achievements of scientists, researchers, and science communicators at all career stages.

      There are prizes available for both individuals and teams, and entrants can either enter themselves or be nominated. The Eureka Prizes are open, but not limited to, those who work in research institutes, government departments, media, corporations, and universities. It’s free to enter and there’s a prize pool of $160,000 to be shared between the winners.

      If you know an individual or team doing outstanding work, why not encourage them to enter?

      Entries close 7pm AEST Friday 28 May

      VIEW THE FULL PRIZE PROGRAM

      Registrations open for ASM

      Registrations are now open for our first ever Virtual Annual Scientific Meeting! Be a part of TSANZSRS21 on 1-2 May 2021 from the comfort of your own home.

      Respirology – Editor’s Choice

      Respirology Issue 26.3 March 2021

      The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial

      Miriam R. Bennett, Catherina L. Chang, Chris Tuffery, Sandra Hopping and Robert J. Hancox

      DOI: 10.1111/resp.13955

      Outcomes of protracted bacterial bronchitis in children: A 5-year prospective cohort study

      Tom J.C. Ruffles, Julie M. Marchant, Ian B. Masters, Stephanie T. Yerkovich, Danielle F. Wurzel, Peter G. Gibson, Greta Busch, Katherine J. Baines, Jodie L. Simpson, Heidi C. Smith-Vaughan, Susan J. Pizzutto, Helen M. Buntain, Gregory Hodge, Sandra Hodge, John W. Upham and Anne B. Chang

      DOI: 10.1111/resp.13950

      ASCOT trial

      ASCOT is a clinical trial that will generate clinical evidence about the most effective treatments and combinations of treatments for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

      The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand, Indian and Denmark. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

      Potential Treatments for COVID-19

      The global response to COVID-19 is working to accelerate diagnostics, vaccines and therapeutics. While remdesivir has been shown to accelerate time to recovery, and low-dose dexamethasone to decrease mortality, more effective therapies are needed.

      ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

      ASCOT Trial Intervention

      ASCOT ADAPT includes 3 treatment domains:

      Domain A (Antiviral)

      1. Standard of care
      2. Standard of care + nafamostat

      Domain B (Antibody)

      1. Standard of care
      2. Standard of care + convalescent plasma

      Domain C (Anticoagulation)

      1. Standard dose thromboprophylaxis
      2. Intermediate dose thromboprophylaxis
      3. Standard dose thromboprophylaxis plus aspirin

      Eligible patients can be randomised to one or more domains concurrently.

      Protocol documents and further details are available at www.ascot-trial.edu.au

       Australasian Society for Medical Research message

      The Thoracic Society is an affiliate member of the ASMR. Please see below for their latest communications.

      Dear ASMR member

      The Australian National Audit Office has informed us that an audit of ‘Health’s Management of the Medical Research Future Fund’ is currently open for contribution. The period for submissions is expected to close on 30 May 2021 and the audit report will be tabled in September 2021.

      “The objective of this audit is to assess whether the Department of Health is effectively managing the Medical Research Future Fund (MRFF)” with respect to the following criteria:

      • “Are the MRFF governance arrangements effective?”
      • “Has MRFF legislation, governance, strategies and priorities guided selection of medical research initiatives?”
      • “Does Health effectively monitor, measure and evaluate MRFF’s performance?”

      Submissions are confidential and can be anonymous (name, address and contact number fields provided are not required for a submission) so I encourage you and your extended networks to contribute instances or evidence around issues relating to the audit criteria for an ASMR submission (please send to president@asmr.org.au), or if you prefer, make a submission directly to the audit webpage.

      While the addition of the MRFF to the health and medical research funding landscape is greatly welcomed, since its inception in 2014, Australian clinicians and researchers have expressed concerns about the MRFF processes and governance. I therefore cannot stress the importance of providing accurate, appropriate and verifiable submissions to the auditors with regard to the audit objective and criteria.

       

      Yours sincerely,
      Dr Ryan Davis
      ASMR President 2021

      Surveys and Research

      SURVEY OF LUNG CANCER CARE IN AUSTRALIA

      We would be grateful please for less than 5 minutes of your time to complete this survey which is designed to provide a snapshot of the current status of lung cancer care and MDTs around Australia.

      • These data will help inform vital services planning for lung cancer care and will directly inform ongoing discussions with Government about lung cancer care across Australia.
      • We are only asking for one response from each institution, we suggest it is the lead clinician for the lung cancer MDT.
      • Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number HRE2021-0031).

      Please follow the link to the Australian-wide Survey of Lung Cancer Care, or use the QR code below.

      Thank you for your time.

      Prof Fraser Brims
      Curtin Medical School
      fraser.brims@curtin.edu.au 

      TOP 10 RESEARCH PRIORITIES FOR PULMONARY FIBROSIS

      A recent research study as part of the NHMRC’s Centre of Research Excellence in Pulmonary Fibrosis grant aimed to identify the top 10 research priorities for pulmonary fibrosis (PF) according to people living with pulmonary fibrosis, caregivers, health professionals and researchers.

      This study has now been completed and below is a summary of the findings from this work.

      The top 3 priorities rank by people with PF and caregivers were:

      1. What medications can reverse scarring in the lungs of people with PF?
      2. What medications can improve lung function in people with PF?
      3. What are the causes of PF?

      The top 3 priorities rank by people with healthcare professionals/researchers were:

      1. What medications can reverse scarring in the lungs of people with PF?
      2. How can we prevent PF?
      3. What are the causes of PF?

      The findings from this study have been published in a peer-reviewed journal and will help guide future research directions.

      (click on the link to view the paper– https://doi.org/10.1136/thoraxjnl-2020-215731)

      The Study team extends their thanks and appreciation to all those who participated in the study for their time and valuable contribution to this work.

      Yours sincerely,

      Anne Holland
      Professor of Physiotherapy (Research), Monash University (anne.holland@monash.edu)

      TBPod

      The TBPod are podcasts designed for clinicians and policymakers with an interest tuberculosis. These podcasts consist of conversations with expert clinicians, researchers, policy makers and advocates about their work in the field of tuberculosis. The TBPod is prepared by ACTnet and the TB Forum and can be found on ITunes, Spotify, and the ACTnet Website.

      Can you help TSANZ make a difference?

      Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

      1. Making a donation to our Benevolent Fund

      The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
      CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      2. Making a donation to support research

      With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
      Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      3. Establishing a named award

      For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

      4. Leave TSANZ a gift in your will

      If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
      If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

      5. TSANZ New Zealand Branch Incorporated 

      New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt.
      CLICK HERE to make a donation.

      Thank you for your continued support of TSANZ.

       

      VOLUME 6.05 – JULY 2021

      VOLUME 6.02 – FEBRUARY 2021

      Research Roundup:

      February 2021

      Welcome Message

      We hope you’ve been keeping safe and well.

      We are pleased to announce that the Boehringer Ingelheim New Zealand Primary Care Grant is now open. This grant aims to support research in respiratory health within the primary care sphere in New Zealand. Primary care can include general practice, allied health services, nursing in community health and community pharmacy.

      Please note that a number of awards are closing this Wednesday 24 February. These include our modified travel awards that take into account travel bans and restrictions.

      Don’t forget to register for our first ever Virtual Annual Scientific Meeting – TSANZSRS21.

      Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below.

      Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

      Enjoy the February edition of your Research Roundup.

      Prof Sandra Hodge
      Chair, Research Sub-Committee

      Open Awards

      Thoracic Society Awards

      TSANZ Indigenous Respiratory Nursing Award – closing 01 April 2021

      Boehringer Ingelheim New Zealand Primary Care Award – closing 05 April 2021

      TSANZ National Asthma Council Australia – Asthma & Airways Fellowship – closing 31 May 2021

      How to participate

      Follow the links above to access each award application form and download the information sheet.

      Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

      Grifols Scientific Awards

      The 18th Annual ALTA Alpha-1-Antitrypsin Laurell’s Training Award is now open.

      Deadline for submission of letter of intent – 1 March 2021

      Deadline for submission of full proposal – 31 May 2021

      Registrations open for ASM

      Registrations are now open for our first ever Virtual Annual Scientific Meeting! Be a part of TSANZSRS21 on 1-2 May 2021 from the comfort of your own home.

      Respirology – Editor’s Choice

      Respirology Issue 26.2 February 2021

      Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial

      Matthias H. Urban, Nicole Kreibich, Andreas Gleiss, Georg-Christian Funk, Sylvia Hartl and Otto C. Burghuber

      DOI: 10.1111/resp.13914

       ASCOT trial

      ASCOT is a clinical trial that will generate clinical evidence about the most effective treatments and combinations of treatments for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

      The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand, Indian and Denmark. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

      Potential Treatments for COVID-19

      The global response to COVID-19 is working to accelerate diagnostics, vaccines and therapeutics. While remdesivir has been shown to accelerate time to recovery, and low-dose dexamethasone to decrease mortality, more effective therapies are needed.

      ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

      ASCOT Trial Intervention

      ASCOT ADAPT includes 3 treatment domains:

      Domain A (Antiviral)

      1. Standard of care
      2. Standard of care + nafamostat

      Domain B (Antibody)

      1. Standard of care
      2. Standard of care + convalescent plasma

      Domain C (Anticoagulation)

      1. Standard dose thromboprophylaxis
      2. Intermediate dose thromboprophylaxis
      3. Standard dose thromboprophylaxis plus aspirin

      Eligible patients can be randomised to one or more domains concurrently.

      Protocol documents and further details are available at www.ascot-trial.edu.au

      Surveys and Research

      SURVEY OF LUNG CANCER CARE IN AUSTRALIA

      We would be grateful please for less than 5 minutes of your time to complete this survey which is designed to provide a snapshot of the current status of lung cancer care and MDTs around Australia.

      • These data will help inform vital services planning for lung cancer care and will directly inform ongoing discussions with Government about lung cancer care across Australia.
      • We are only asking for one response from each institution, we suggest it is the lead clinician for the lung cancer MDT.
      • Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number HRE2021-0031).

      Please follow the link to the Australian-wide Survey of Lung Cancer Care, or use the QR code below.

      Thank you for your time.

      Prof Fraser Brims
      Curtin Medical School
      fraser.brims@curtin.edu.au 

      TOP 10 RESEARCH PRIORITIES FOR PULMONARY FIBROSIS

      A recent research study as part of the NHMRC’s Centre of Research Excellence in Pulmonary Fibrosis grant aimed to identify the top 10 research priorities for pulmonary fibrosis (PF) according to people living with pulmonary fibrosis, caregivers, health professionals and researchers.

      This study has now been completed and below is a summary of the findings from this work.

      The top 3 priorities rank by people with PF and caregivers were:

      1. What medications can reverse scarring in the lungs of people with PF?
      2. What medications can improve lung function in people with PF?
      3. What are the causes of PF?

      The top 3 priorities rank by people with healthcare professionals/researchers were:

      1. What medications can reverse scarring in the lungs of people with PF?
      2. How can we prevent PF?
      3. What are the causes of PF?

      The findings from this study have been published in a peer-reviewed journal and will help guide future research directions.

      (click on the link to view the paper– https://doi.org/10.1136/thoraxjnl-2020-215731)

      The Study team extends their thanks and appreciation to all those who participated in the study for their time and valuable contribution to this work.

      Yours sincerely,

      Anne Holland
      Professor of Physiotherapy (Research), Monash University (anne.holland@monash.edu)

      TBPod

      The TBPod are podcasts designed for clinicians and policymakers with an interest tuberculosis. These podcasts consist of conversations with expert clinicians, researchers, policy makers and advocates about their work in the field of tuberculosis. The TBPod is prepared by ACTnet and the TB Forum and can be found on ITunes, Spotify, and the ACTnet Website.

      Can you help TSANZ make a difference?

      Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

      1. Making a donation to our Benevolent Fund

      The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
      CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      2. Making a donation to support research

      With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
      Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      3. Establishing a named award

      For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

      4. Leave TSANZ a gift in your will

      If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
      If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

      5. TSANZ New Zealand Branch Incorporated 

      New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt.
      CLICK HERE to make a donation.

      Thank you for your continued support of TSANZ.

      VOLUME 6.05 – JULY 2021

      VOLUME 5.06 – SEPTEMBER 2020

      Research Roundup:

      September 2020

      Welcome Message

      Welcome to another edition of our TSANZ Research Roundup. We hope that you remain well during this difficult time, and our thoughts are especially with our Victorian members who are on the front-line treating patients with COVID or facing unprecedented restrictions.

      Plans for our exciting first virtual ASM in 2021 are well underway, with abstract submissions opened on 21 September 2020 and registrations opening on 22 October 2020. Please visit our TSANZSRS2021 website for more details about abstracts, and pay close attention to the closing date of 6 November 2020. Abstracts submitted to the 2020 Annual Scientific Meeting are eligible to be resubmitted for the 2021 Annual Scientific Meeting, and all resubmitted abstracts will undergo the same robust peer review process for allocation to oral or poster sessions.

      The TSANZ Webinar Series continue, with the Society Medal and 50th Anniversary Medalpresentations on 30 September, so don’t forget to register for these exciting events.  

      Please also note the opening of the following awards that are now accessible on the TSANZ Awards Submission Portal:

      • Past Presidents Scholarship Award: this new award will support national or international travel costs to present research for early career researchers who do not have the resources available to them via their institution or workplace. Importantly, the awardee will have the support from a TSANZ Past President who will provide invaluable feedback and professional development guidance to help them develop their research presentation skills.
      • Boehringer Ingelheim New Zealand Primary Care Grant: this award addresses the issue of access to primary care in New Zealand, particularly during restrictions like those faced during the COVID-19 pandemic.

      In addition, we are pleased to announce the new CREATE PhD Scholarship, and the opening of LFA Awards:

      Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below.

      Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

      Enjoy the September edition of your Research Roundup.

      Prof Sandra Hodge

      Chair, Research Sub-Committee

      Call for Abstracts

      Abstracts for TSANZSRS21 are now open. Abstracts submitted to the 2020 Annual Scientific Meeting are eligible to resubmit for the 2021 Annual Scientific Meeting. Please note, all resubmitted abstracts will undergo the same robust peer review process for allocation to oral or poster sessions.

      Please submit your abstract by 6 November and join us for our first ever virtual ASM in 2021!

       

      New Award: CREATE Hope Research Fund PhD Scholarships in Pulmonary Fibrosis

      The CREATE PhD Scholarships in Pulmonary Fibrosis will support research into pulmonary fibrosis in Australia

      Relevant domains of research inquiry include any form of clinical, population, laboratory, genetic or tissue based research. 

      Students who are wishing to undertake a PhD, or are currently enrolled in a PhD in Pulmonary Fibrosis Research, are invited to submit an application. The student must be a resident in Australia throughout the period of the research program.

      The Centre of Research Excellence in Pulmonary Fibrosis (the CRE-PF)  will allocate a total of two grants, each of $28,000, for the PhD Scholarships. These scholarships will either fund a stipend for one year for a full time student or may be extended over a second year, should the student be able to secure matching funds to permit extension of the period via their University or Research Institute. Extension of the funding in order to extend the value of the research investment by the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) and Lung Foundation Australia by securing matching funding from the host institution is encouraged and will be regarded favourably.

      These funds are to be used for the student stipend. Direct, indirect research costs and/or infrastructure costs do not form part of this grant and will not be covered by this funding.

      Click here for more info!

      Open Awards

      Thoracic Society Awards

      TSANZ Past Presidents Scholarship Award – closing 04 October 2020

      Boehringer Ingelheim New Zealand Primary Care Grant – closing 04 October 2020

      TSANZ ASM 2021 abstract-linked Awards – closing 6 November 2020

       Lung Foundation Awards

      Lizotte Family Idiopathic Pulmonary Fibrosis Research Grant – closing 13 October 2020

      Ludwig Engel Grant-in-Aid for Physiological Respiratory Research – closing 13 October 2020

      Ivan Cash Grant-in-Aid For Idiopathic Pulmonary Fibrosis Research – closing 13 October 2020

      Cochrane Airways Australia Scholarship – closing 13 October 2020

      Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF)

      CREATE Hope Research Fund PhD Scholarships in Pulmonary Fibrosis – closing 31 October 2020

      How to participate

      Follow the links above to access each award application form and download the information sheet.

      Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

      Respirology – Special Issue and Editor’s Choice
       

      Respirology Issue 25.9 September 2020

       

      Special Issue: Interventional Pulmonology Pearls

       

      Cover caption: A collection of images from the Invited review series International Pumlonology Pearls.

      Illustrations credit (A to F clockwise from top left) : A and B: Pyng Lee (personal communication), C and D: Fielding and Oki p.914, E: Guibert et al. p.953, F: Shah and Slebos p.972.

      DOI: 10.1111/resp.13598

       

      Respirology Issue 25.10 October 2020

       

      Acute effects of e-cigarette vaping on pulmonary function and airway inflammation in healthy individuals and in patients with asthma

      Serafeim-Chrysovalantis Kotoulas, Athanasia Pataka, Kallipoi Domvri, Dionisios Sypratos, Paraskevi Katsaounou, Konstantinos Porpodis, Evangelia Fouka, Aikaterini Markopoulou, Katalin Passa-Fekte, Ioanna Grigoriou, Theodoros Kontakiotis, Paraskevi Argyropoulou and Despoina Papakosta

       

      Cover caption: Asthmatic and healthy smokers underwent pulmonary function tests to assess acute effects of e-cigarettes

      DOI: 10.1111/resp.13806

       

      Peer Connect Service for people with pulmonary fibrosis in Australia: Participants’ experiences and process evaluation

      Gabriella Tikellis, Joanna Y.T. Lee, Tamera J. Corte, Jamie Maloney, Michael Bartlett, Tonia Crawford, Ian N. Glaspole, Nicole Goh, Kelcie Herrmann, Alison J. Hey-Cunningham, Greg Keir, Yet H. Khor, John Price, Debra G. Sandford, Lissa Spencer, Alan Teoh, Jennifer Walsh, Susanne Webster and Anne E. Holland

       

      Cover caption:  Bill, diagnosed with IPF in 2015, is a primary peer within the Pulmonary Fibrosis Peer Connect service. (Photograph credit: Lung Foundation Australia)

      DOI: 10.1111/resp.13807

      Invitations and surveys

      BREATHE Study

      Do you have asthma, emphysema, chronic bronchitis or bronchiectasis?

      Do you live in an area affected by bushfires or bushfire smoke?

      If yes to both, you may be eligible for the BREATHE study.

      We are studying facemasks for prevention of smoke exposure

      Find out more: https://kirby.unsw.edu.au/breathe

      Please register your interest: https://www.surveymonkey.com/r/C96DXJN

      Contact us: e.kpozehouen@unsw.edu.au

      Ethics Approval: HC200477

      INVITATION TO PARTICIPATE IN AN ERS STUDY AIMING TO IMPROVE THE QUALITY OF CLINICAL TRIALS EVALUATING THE MANAGEMENT OF COPD EXACERBATIONS

      Dear colleagues,

      Clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations evaluate heterogeneous outcomes (endpoints), often omitting those that are clinically important and relevant to patients. This limits their usability and comparability.

      To remedy this issue, the European Respiratory Society (ERS) set-up a Task Force aiming to develop a core outcome set (COS). A COS is a consensus-based minimum set of clinically important outcomes that should be evaluated in all future clinical trials on the management of COPD exacerbations.

      We have identified around 50 outcomes of COPD exacerbations and we need your help to prioritize a small number of the most important outcomes, to be included in the core outcome set and to be evaluated in all future clinical trials on the management of COPD exacerbations. To help us prioritize the outcomes, we will be grateful if you could complete a survey that has two stages, 4-8 weeks apart. Each survey takes about 20 minutes to complete.

      In the first survey, you will be asked to rate the importance of 50 outcomes between 1-9:

      • 1-3: Outcomes of limited importance.
      • 4-6: Outcomes that are important but not critical.
      • 7-9: Critical outcomes.

      We welcome responses from health professionals, researchers, patients with COPD and any other stakeholders with interest in COPD exacerbations.

      In the second survey, you will see a graph summarizing the responses of all participants in the first survey and you will be asked to reconsider your ratings, taking into consideration the views of the other responders. While the aim of this survey will be to reach consensus, you will not have to change your ratings if you do not want to.

      Your opinion in both surveys is extremely important in developing the core outcome set.

      It is crucial that you complete both surveys and we would be very grateful if you can do this.

      Please, take the survey in one of the following languages:

      English: https://delphimanager.liv.ac.uk/COPD/
      Portuguese: https://delphimanager.liv.ac.uk/COPD-PO/
      German: https://delphimanager.liv.ac.uk/COPD-GE/
      Hungarian:  https://delphimanager.liv.ac.uk/COPD-HU/
      Mandarin: https://delphimanager.liv.ac.uk/COPD-CN/
      Spanish: https://delphimanager.liv.ac.uk/COPD-ES/
      Russian: https://delphimanager.liv.ac.uk/COPD-RU/
      Greek: https://delphimanager.liv.ac.uk/COPD-GR/
      Danish: https://delphimanager.liv.ac.uk/COPD-DK/
      Italian: https://delphimanager.liv.ac.uk/COPD-IT/

      We appreciate this is a difficult time for patients and professionals in the respiratory community. While all efforts should rightly be focused on caring for those affected by the novel coronavirus and COVID-19, we believe that research to improve care and outcomes for respiratory patients is needed now more than ever. We are sensitive to the enormous pressures faced by patients and professionals in our community and will review the timelines for this survey and subsequent work in response to the ongoing global pandemic.

      Thank you very much in advance,
      Kind regards,
      Associate Prof. Jens-Ulrik Jensen,
      Dr. Alexander Mathioudakis,
      Prof. Jørgen Vestbo,
      On behalf of the study team.

       

      GLOBAL CURRENT PRACTICES OF MECHANICAL VENTILATION MANAGEMENT IN COVID-19 PATIENTS

      Dear Colleague, 

      You are invited to partake in the current study, “Global Current Practices of Mechanical Ventilation Management in COVID-19 Patients.” The goal of this study is to explore the current practices of mechanical ventilation support in adult COVID-19 patients worldwide. 

      We are carrying out this online survey for frontline clinicians involved in the care of patients with COVID-19, with the aim to examine which ventilation techniques healthcare providers’ used to manage adult COVID-19 patients. It would be helpful if you could complete this survey, the estimated time is 5-10 minutes. While there is limited information available on ventilatory support practices in COVID-19 patients, this international survey will provide further insights into current strengths and limitations of global practices.

      Rest assured that your answers will be kept confidential, and no information will be used to identify you or your response. This research project was approved by the Institutional Review Board (IRB), AFHER-IRB-2020-012.

      If you have any concern or question regarding this study, please do not hesitate to contact me at Jaber.alqahtani.18@ucl.ac.uk.

      THANK YOU!
      Jaber Alqahtani
      On behalf of the whole international team

       

      INVITATION TO PARTICIPATE IN A STUDY ON SELF MANAGEMENT FOR PULMONARY FIBROSIS: WHAT DOES IT MEAN AND HOW MIGHT IT HELP?

      Dear Members of the Thoracic Society of Australia and New Zealand, 

      Alfred Health and the Centre of Research Excellence in Pulmonary Fibrosis are inviting health professionals involved with pulmonary fibrosis (PF) to take part in a study on self-management for pulmonary fibrosis: what does it mean and how might it help? 

      Participation is voluntary and involves you sharing your views, opinions and experiences on the patients’ management of PF through a confidential telephone interview of about 30 minutes in duration

      Your perspective is important to help us identify and develop resources that will provide patients with the knowledge and tools to manage their own wellbeing. In turn, this will help health professionals to be better equipped to provide support to people with PF and their families. 

      The study has been approved by the Alfred Health Human Ethics Committee (Project number: 144/20). 

      If you are interested in participating or would like further information on this study, please contact: 

      Professor Anne Holland (Chief Investigator) 
      Professor of Physiotherapy, 
      Monash University and Alfred Health 
      Email: Anne.Holland@monash.edu 
      Telephone: (03) 9903 0214 

      Ms Joanna Lee (PhD candidate)
      Monash University and Alfred Health
      Email: joanna.lee2@monash.edu
      Mobile: 0431 689 361

      Thank you for your time and consideration of our study. 

      ASCOT trial

      ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

      The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand and Asia. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

      Potential Treatments for COVID-19

      There are currently no specific therapies for COVID-19. The two main strategies are to limit the virus replicating (antiviral therapies) or to modulate the immune response (in some severe cases, there is a damaging over exuberant immune response).

      ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

      ASCOT Trial Intervention

      Initially, an open label trial of two existing treatments in a 2×2 factorial design with usual care arm will be conducted.

      1. Lopinavir/ritonavir (kaletra), a combination medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection
      1. Hydroxychloroquine, a medicine used to treat rheumatoid arthritis and other inflammatory conditions and to prevent and treat malaria.

      Protocol documents and further details are available at www.ascot-trial.edu.au

       

      Can you help TSANZ make a difference?
       

      Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

      1. Making a donation to our Benevolent Fund

      The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
      CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      2. Making a donation to support research

      With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
      Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      3. Establishing a named award

      For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

      4. Leave TSANZ a gift in your will

      If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
      If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

      5. TSANZ New Zealand Branch Incorporated 

      New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt. 
      CLICK HERE to make a donation.

      Thank you for your continued support of TSANZ

      .

       

      VOLUME 6.05 – JULY 2021

      VOLUME 5.05 – AUGUST 2020

      Research Roundup:

      August 2020

      .

      Welcome Message

      Welcome to the August Research Roundup. We hope you are all staying well in these uneasy COVID-19 times.

      This month we are pleased to open two new awards. Firstly, we are very excited to announce and gratefully acknowledge the generous donation from our immediate past president, Prof Allan Glanville, to establish the Past Presidents Scholarship Award. We hope that others will join him in supporting this award that will provide both funding for our ECRs and, provide access to professional mentors and networks. Given global travel restrictions, ECRs are encouraged to think creatively when applying and consider the merit in visiting institutions closer to home.

      Secondly, we would like to thank Boehringer Ingelheim New Zealand for supporting a new award for our New Zealand members. The Boehringer Ingelheim New Zealand Primary Care Grant aims to support research which will address the issue of access to primary care in New Zealand, particularly during restrictions like those faced during the COVID-19 pandemic. Primary care can include general practice, allied health services, community health and community pharmacy.

      As you would be aware, TSANZ is part of the National COVID-19 Clinical Evidence Taskforce; a living guideline which is continuously updated as new peer reviewed research becomes available. Many of our members are contributing to the COVID-19 research effort. One large multi-centre trial is the ASCOT trial (AustralaSian COVID-19 Trial) which many of our members are involved in. This trial will which be featured in a TSANZ webinar on 17 September 20.

      We are pleased to again be hosting the LFA Awards. These will be opening on the 1st of September, including the Lizotte Family Research Award for IPF Research; Ludwig Engel Grant-in-Aid for Physiological Research; Ivan Cash Grant-in-Aid for IPF Research; and the Cochrane Airways Australia Scholarship. Please see below for more details.

      As TSANZ members we also have the privilege of participating in an increasing number of surveys as detailed below. These include surveys of the Breathe Study: Investigating the role of masks for patients with asthma and COPD against bushfire smoke, Cystic Fibrosis Australia Research and Advocacy Priority Setting, and studies aimed at improving the quality of clinical trials evaluating  the management of COPD exacerbations, nurses’ attitudes to caring for people with intellectual disability, global current practices of mechanical ventilation management in COVID-19 patients, self-management for pulmonary fibrosis and  identifying the barriers and facilitators to the implementation of best practice for the diagnosis, treatment and management of PF. These are all very worthy studies and we encourage your participation.

      Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below

      Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

      Enjoy the August edition of your Research Roundup.

      Prof Sandra Hodge

      Chair, Research Sub-Committee

      TSANZ Past President’s Award

      The TSANZ Past Presidents Scholarship Award aims to support early career researchers (ECRs) who do not have the resources available to them via their institution or workplace to:

      1)  Develop their presentation of research skills, and/or

      2) Present their research at a national or international professional conference of their choice.

      The Scholarship will cover

      • Airfares
      • Accommodation
      • Ground travel and transfers
      • Registration
      • Per Diem Daily Allowance in accordance with the ATO Reasonable Travel and Meal Allowance Guide

      Up to a maximum of AUD 7000, with the amount to be paid dependent on the delivery of receipts for the expenses incurred above.

      Additionally, the Scholarship will provide the awardee with support from a TSANZ Past President to review their presentation and provide feedback and professional development on research presentation skills. The Past President will be determined by TSANZ.

      Please visit the TSANZ Awards Submissions Portal for more information.

      Boeringer Ingelheim New Zealand Primary Care Grant

      The Boehringer Ingelheim New Zealand Primary Care Grant aims to support research which will address the issue of access to primary care in New Zealand, particularly during restrictions like those faced during the COVID-19 pandemic.

      Primary care can include general practice, allied health services, community health and community pharmacy.

      The grant is valued at NZD 5000 and will support studies for one year only.

      Please visit the TSANZ Awards Submissions Portal for more information.

      CREATE Grant-in-Aid Funding Opportunity

      In 2020, there is a CREATE Grant-in-Aid opportunity for the award of one or more grants valued at a total of $7,000 to assist new collaborative investigator led Pulmonary Fibrosis research within the group of CREATE Fellows. The objective of the CREATE Grant-in-Aid is to encourage new research which meets the aims of the CRE-PF and builds collaborations between CREATE Fellows drawn together through the CRE-PF.

      Please visit the LFA Awards Submissions Portal for more information.

      LFA Awards

      Lung Foundation Australia and its partners are excited to announce the following Research Grants will be open to application from 1 September 2020. For more information visit: https://lungfoundation.com.au/research/awards-and-grants/apply-for-funding/

      YEAR OPEN

      YEAR UNDERTAKEN

      Award 

      Target area 

      Value

      Duration

      Timeline

      2020

      2021

      Lung Foundation Australia – Lizotte Family Grant for IPF Research 

      IPF 

       $        5,000.00 

      1 year

      1 September 2020 (close 13 October, announced 11 Dec) 

      2020

      2021

      Lung Foundation Australia – Ludwig Engel Grant-in-Aid for Physiological Respiratory Research

      IPF 

       $        5,000.00 

      1 year

      1 September 2020 (close 13 October, announced 11 Dec) 

      2020

      2021

      Lung Foundation Australia -Ivan Cash Grant-in-Aid For IPF Research

      IPF 

       $        5,000.00 

      1 year

      1 September 2020 (close 13 October, announced 11 Dec) 

      2020

      2021

      Lung Foundation Australia -Cochrane Airways Australia 
      Scholarship

      Systematic Review

      $        2,500.00 

      1 year

      1 September 2020 (close 13 October, announced 11 Dec) 

       

      LFA 2020 Research Grant recipients

       

      Congratulations to the recipients of the Lung Foundation Australia 2020 Research Grants.

      2019

      2020

      Lung Foundation Australia – Ellen Yates Memorial Grant in Aid for Lung Cancer Research

      $20,000.00 

      Edith Cowan University

      Dr. Afaf Abed

      2019

      2020

      Lung Foundation Australia – Deep Manchanda Fellowship in Lung Cancer Research

      $   160,000.00 

      The Garvan Institute of Medical Research

      Dr. Venessa Chin

      2019

      2020

      Lung Foundation Australia – Di Cox PhD Scholarship in IPF Research 

       $      45,000.00 

       University of Sydney

      Dr. Laura Glenn

      2019

      2020

      Lung Foundation Australia – Brian Eaton PhD Scholarship in IPF Research 

       $      45,000.00 

       University of Sydney

      Dr. Matthew Parker

      2019

      2020

      Lung Foundation Australia – Lizotte Family Grant for IPF Research

      $        5,000.00 

      Austin Health

      Dr Yet Hong Khor

      2019

      2020

      Lung Foundation Australia – Ludwig Engel Grant-in-Aid for Physiological Respiratory Research

      $        5,000.00 

      The Children’s Hospital at Westmead

      Dr. Alexander Wong 

      2019

      2020

      Lung Foundation Australia – Ivan Cash Grant-in-Aid For IPF Research

      $        5,000.00 

      RMIT University 

      Dr. Paris Papagianis

      2019

      2020

      Lung Foundation Australia – Cochrane Airways Australia 
      Scholarship

      $        2,500.00 

      University of South Australia

      Kelsey Sharrad

       

      Australasian Severe Asthma Registry (ASAR) Annual Report 2019

       

      TSANZ is excited to share the ASAR 2019 Annual Report with you!

      In 2019, TSANZ in collaboration with the Australasian Severe Asthma Network (ASAN), successfully transitioned the Severe Asthma Web-based Database (SAWD) to ASAR – a Clinical Quality Registry (CQR). ASAR is now uniquely positioned to collect longitudinal data (10-year follow-up) on a well-characterised severe asthma cohort in Australia and New Zealand with the capability to add modules of specific interest, for example, the Australasian Benralizumab Registry.

      To view the ASAR 2019 Annual Report please click here.

      Respirology – Editor’s Choice 

      Respirology Issue 25.7 July 2020

       

      Sputum transcriptomics implicates increased p38 signalling activity in severe asthma

      Katherine J. Baines, Michael Fricker, Vanessa M. McDonald, Jodie L. Simpson, Lisa G. Wood, Peter A.B. Warik, Heather E. Macdonald, Andrew Reid and Peter G. Gibson

       

      The authorship team from Hunter Medical Research Institute, The University of Newcastle, Newcastle, Australia

      DOI: 10.1111/resp.13749

       

      Impact of chronic obstructive pulmonary disease on mortality: A large national cohort study

      Hye Yun Park, Danbee Kang, Hyun Lee, Sun Hye Shin, Minwoong Kang, Sunga Kong, Chin Kook Rhee, Juhee Cho and Kwang Ha Yoo

       

      The Korean COPD And Outcomes Study Team. From left to right: (Top) Kwang Ha Yoo, Danbee Kang, Sun Hye Shin, (Bottom) Juhee Cho and Hye Yun Park

      DOI: 10.1111/resp.13678

      Respirology Issue 25.8 August 2020

       

      Ventilation heterogeneity and oscillometry predict asthma control improvement following step-up inhaled therapy in uncontrolled asthma

      Francesca S.M. Tang, Sandra Rutting, Catherine E. Farrow, Katrina O. Tonga, Joanna Watts, Jessica R. Dame-Carrol, Amy Bertolin, Gregory G. King, Cindy Thamrin and David G. Chapman

       

      The Airway Physiology and Imaging Group from the Woolcock Institute of Medical Research in Sydney, Australia, as part of the overall research team. From left to right: Prof. Gregory King, Dr David Chapman, Dr Sandra Rutting, Dr Katrina Tonga and A/Prof. Cindy Thamrin.

      DOI: 10.1111/resp.13772

       

      Identification and definition of asthma–COPD overlap: The CanCOLD study

      Miriam Barrecheguren, Lancelot Pinto, Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi, Wan C. Tan, Pei Z. Li, Shawn D. Aaron, Andrea Benedetti, Kenneth R. Chapman, Brandie Walker, J. Mark Fitzgerald, Paul Hernandez, François Maltais, Darcy D. Marciniuk, Denis E. O’Donnell, Don D. Sin, Jean Bourbeau for The Cancold Collaborative Research Group and The Canadian Respiratory Research Network

       

      The authorship team on behalf of the CanCOLD Collaborative Research Group and

      the Canadian Respiratory Research Network. From top left to right bottom: Miriam Barrecheguren, Lancelot Pinto, Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi, Wan Tan, Pei Li, Shawn Aaron, Andrea Benedetti, Kenneth Chapman, B Walker, Mark Fitzgerald, Paul Hernandez, François Maltais, Darcy Marciniuk, Denis O’Donnell, Don Sin, Jean Bourbeau

      DOI: 10.1111/resp.13780

      Invitations and surveys

      BREATHE Study

      Do you have asthma, emphysema, chronic bronchitis or bronchiectasis?

      Do you live in an area affected by bushfires or bushfire smoke?

      If yes to both, you may be eligible for the BREATHE study.

      We are studying facemasks for prevention of smoke exposure

      Find out more: https://kirby.unsw.edu.au/breathe

      Please register your interest: https://www.surveymonkey.com/r/C96DXJN

      Contact us: e.kpozehouen@unsw.edu.au

      Ethics Approval: HC200477

      CYSTIC FIBROSIS RESEARCH AND ADVOCACY PRIORITY SETTING SURVEY 2020 AND BEYOND

      Dear Members of the Thoracic Society of Australia and New Zealand,

      Cystic Fibrosis Australia (CFA) is inviting the TSANZ members to take part in their Research and Advocacy Priority Setting survey. If you are a CF stakeholder, living with the condition or looking after someone who lives with the condition, then your survey responses are greatly needed and encouraged.

      https://www.surveymonkey.com/r/F38Q8K2

      We want all our community members, patients, carers, clinicians and researchers to be involved in every step and we thank you for agreeing to take part.

      To speak to us about this questionnaire or for any further enquires, contact us at (02) 9889 5171 or email nickim@cfa.org.au. Alternatively, you can join the conversation over at the Cystic Fibrosis Australia page on Facebook.

       

      INVITATION TO PARTICIPATE IN AN ERS STUDY AIMING TO IMPROVE THE QUALITY OF CLINICAL TRIALS EVALUATING THE MANAGEMENT OF COPD EXACERBATIONS

      Dear colleagues,

      Clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations evaluate heterogeneous outcomes (endpoints), often omitting those that are clinically important and relevant to patients. This limits their usability and comparability.

      To remedy this issue, the European Respiratory Society (ERS) set-up a Task Force aiming to develop a core outcome set (COS). A COS is a consensus-based minimum set of clinically important outcomes that should be evaluated in all future clinical trials on the management of COPD exacerbations.

      We have identified around 50 outcomes of COPD exacerbations and we need your help to prioritize a small number of the most important outcomes, to be included in the core outcome set and to be evaluated in all future clinical trials on the management of COPD exacerbations. To help us prioritize the outcomes, we will be grateful if you could complete a survey that has two stages, 4-8 weeks apart. Each survey takes about 20 minutes to complete.

      In the first survey, you will be asked to rate the importance of 50 outcomes between 1-9:

      • 1-3: Outcomes of limited importance.
      • 4-6: Outcomes that are important but not critical.
      • 7-9: Critical outcomes.

      We welcome responses from health professionals, researchers, patients with COPD and any other stakeholders with interest in COPD exacerbations.

      In the second survey, you will see a graph summarizing the responses of all participants in the first survey and you will be asked to reconsider your ratings, taking into consideration the views of the other responders. While the aim of this survey will be to reach consensus, you will not have to change your ratings if you do not want to.

      Your opinion in both surveys is extremely important in developing the core outcome set.

      It is crucial that you complete both surveys and we would be very grateful if you can do this.

      Please, take the survey in one of the following languages:

      English: https://delphimanager.liv.ac.uk/COPD/
      Portuguese: https://delphimanager.liv.ac.uk/COPD-PO/
      German: https://delphimanager.liv.ac.uk/COPD-GE/
      Hungarian:  https://delphimanager.liv.ac.uk/COPD-HU/
      Mandarin: https://delphimanager.liv.ac.uk/COPD-CN/
      Spanish: https://delphimanager.liv.ac.uk/COPD-ES/
      Russian: https://delphimanager.liv.ac.uk/COPD-RU/
      Greek: https://delphimanager.liv.ac.uk/COPD-GR/
      Danish: https://delphimanager.liv.ac.uk/COPD-DK/
      Italian: https://delphimanager.liv.ac.uk/COPD-IT/

      We appreciate this is a difficult time for patients and professionals in the respiratory community. While all efforts should rightly be focused on caring for those affected by the novel coronavirus and COVID-19, we believe that research to improve care and outcomes for respiratory patients is needed now more than ever. We are sensitive to the enormous pressures faced by patients and professionals in our community and will review the timelines for this survey and subsequent work in response to the ongoing global pandemic.

      Thank you very much in advance,
      Kind regards,
      Associate Prof. Jens-Ulrik Jensen,
      Dr. Alexander Mathioudakis,
      Prof. Jørgen Vestbo,
      On behalf of the study team.

       

      NURSES’ ATTITUDES TO CARING FOR PEOPLE WITH INTELLECTUAL DISABILITY: AN AUSTRALIAN SURVEY

      Dear Colleagues,

      We invite you to consider participating in our online survey focused on nurses’ attitudes to caring for people with intellectual disability. This survey, led by researchers from Western Sydney and Central Queensland Universities, is a replication of a previous US study by Dr Melissa Desroches from the University of Massachusetts, Dartmouth.

      People with intellectual disability have lower levels of general health than other members of our community. They also have higher incidence of hospitalisation and, of major concern, higher incidence of preventable death than members of the general population.

      By learning about nurses’ attitudes to caring for people with intellectual disability, we anticipate being able to develop models of care and supportive resources for nurses to enhance the care that they provide to people with intellectual disability.

      Please read the attached participant information sheet and consider completing this short survey by accessing the link below:

      Caring for People with Intellectual Disability survey

      Thank you for considering our invitation
      A/Prof Nathan Wilson, Western Sydney University
      Dr Peter Lewis, Western Sydney University
      Ms Virginia Howie, Central Queensland University
      Dr Melissa Desroches, University of Massachusetts, Dartmouth

      Kind regards,
      Virginia

       

      GLOBAL CURRENT PRACTICES OF MECHANICAL VENTILATION MANAGEMENT IN COVID-19 PATIENTS

      Dear Colleague, 

      You are invited to partake in the current study, “Global Current Practices of Mechanical Ventilation Management in COVID-19 Patients.” The goal of this study is to explore the current practices of mechanical ventilation support in adult COVID-19 patients worldwide. 

      We are carrying out this online survey for frontline clinicians involved in the care of patients with COVID-19, with the aim to examine which ventilation techniques healthcare providers’ used to manage adult COVID-19 patients. It would be helpful if you could complete this survey, the estimated time is 5-10 minutes. While there is limited information available on ventilatory support practices in COVID-19 patients, this international survey will provide further insights into current strengths and limitations of global practices.

      Rest assured that your answers will be kept confidential, and no information will be used to identify you or your response. This research project was approved by the Institutional Review Board (IRB), AFHER-IRB-2020-012.

      If you have any concern or question regarding this study, please do not hesitate to contact me at Jaber.alqahtani.18@ucl.ac.uk.

      THANK YOU!
      Jaber Alqahtani
      On behalf of the whole international team

       

      INVITATION TO PARTICIPATE IN A STUDY ON SELF MANAGEMENT FOR PULMONARY FIBROSIS: WHAT DOES IT MEAN AND HOW MIGHT IT HELP?

      Dear Members of the Thoracic Society of Australia and New Zealand, 

      Alfred Health and the Centre of Research Excellence in Pulmonary Fibrosis are inviting health professionals involved with pulmonary fibrosis (PF) to take part in a study on self-management for pulmonary fibrosis: what does it mean and how might it help? 

      Participation is voluntary and involves you sharing your views, opinions and experiences on the patients’ management of PF through a confidential telephone interview of about 30 minutes in duration

      Your perspective is important to help us identify and develop resources that will provide patients with the knowledge and tools to manage their own wellbeing. In turn, this will help health professionals to be better equipped to provide support to people with PF and their families. 

      The study has been approved by the Alfred Health Human Ethics Committee (Project number: 144/20). 

      If you are interested in participating or would like further information on this study, please contact: 

      Professor Anne Holland (Chief Investigator) 
      Professor of Physiotherapy, 
      Monash University and Alfred Health 
      Email: Anne.Holland@monash.edu 
      Telephone: (03) 9903 0214 

      Ms Joanna Lee (PhD candidate)
      Monash University and Alfred Health
      Email: joanna.lee2@monash.edu
      Mobile: 0431 689 361

      Thank you for your time and consideration of our study. 

       

      IDENTIFYING BARRIERS AND FACILITATORS TO THE IMPLEMENTATION OF BEST PRACTICE FOR PULMONARY FIBROSIS IN AUSTRALIA

      What are the barriers and facilitators to implementing best practice?

      Dear Members of the Thoracic Society of Australia and New Zealand,

      The Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is inviting physicians involved in the management of people with pulmonary fibrosis (PF) to take part in our study aimed at identifying the barriers and facilitators to the implementation of best practice for the diagnosis, treatment and management of the disease.

      Participation is voluntary and involves providing your views, opinions and experiences on the management of PF through confidential, in person interviews of about 30 minutes in duration. 

      Your perspective is important to help us understand the barriers that may be impeding the implementation of best practice in clinical settings. The findings have the potential to guide the development of behaviour change strategies aimed at improving implementation and in turn, optimise the prognosis and management pathways for people with this insidious disease.

      Like more information or interested in participating? Click here

      The study has been approved by the Monash University Human Ethics Committee (Number 22350) and the Sydney Local Health District Human Ethics Committee (Number 2019/ETH13556).

      If you would like to speak to us about any aspect of this study, please contact:

      Professor Anne Holland
      Professor of Physiotherapy, Monash University and Alfred Health
      Department of Allergy, Clinical Immunology and Respiratory Medicine, Monash University
      Anne.Holland@monash.edu or (03) 9903 0214

      Thank you for your time and consideration of our study.

      ASCOT trial

      ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

      The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand and Asia. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

      Potential Treatments for COVID-19

      There are currently no specific therapies for COVID-19. The two main strategies are to limit the virus replicating (antiviral therapies) or to modulate the immune response (in some severe cases, there is a damaging over exuberant immune response).

      ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

      ASCOT Trial Intervention

      Initially, an open label trial of two existing treatments in a 2×2 factorial design with usual care arm will be conducted.

      1. Lopinavir/ritonavir (kaletra), a combination medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection
      1. Hydroxychloroquine, a medicine used to treat rheumatoid arthritis and other inflammatory conditions and to prevent and treat malaria.

       

      Protocol documents and further details are available at www.ascot-trial.edu.au

       

      Can you help TSANZ make a difference?
       

      Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

      1. Making a donation to our Benevolent Fund

      The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
      CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      2. Making a donation to support research

      With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
      Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      3. Establishing a named award

      For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

      4. Leave TSANZ a gift in your will

      If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
      If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

      5. TSANZ New Zealand Branch Incorporated 

      New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt. 
      CLICK HERE to make a donation.

      Thank you for your continued support of TSANZ.

      VOLUME 6.05 – JULY 2021

      VOLUME 5.04 – JUNE 2020

      Research Roundup:

      June 2020

       

      Welcome Message

      Welcome to this exciting update of the Research Roundup.

      Many of you would have experienced the success of our first virtual Ann Woolcock Award presentation session. I congratulate all the finalists for adapting so well to this new format and to the audience who quickly settled into the Zoom Q&A system and challenged the speakers with stimulating questions.

      The RSC members are having a well-earned break from their arduous but rewarding grant review duties, and both I and the Society sincerely thank these members for all their hard work. Their break will be short as awards will open again in the coming months.

      Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

      Enjoy the June edition of your Research Roundup.

      Prof Sandra Hodge

      Chair, Research Sub-Committee

      2020 Respiratory Research Excellence Awards

       

      TSANZ congratulates the following award winners!!!

       

      Ann Woolcock New Investigator Award Winner: Kurtis Budden

      Ann Woolcock New Investigator Award Finalists: Kak-Ming Ling, Rebecca Stockwell, Steven Taylor, Pamela Laird, Razia Zakarya

      TSANZ and National Asthma Council Australia Asthma and Airways Career Development Fellowship: Simon Craig

      TSANZ/AstraZeneca Respiratory Research Mid-Career Fellowship: Hayley Scott

      TSANZ/AstraZeneca Respiratory Research Early Career Fellowship: Steven Taylor

      Australian Cystic Fibrosis Research Trust 2020 Innovation Grant: Abdullah Tarique, Peter Sly, Emmanuelle Fantino, Clair Wainwright, and Scott Bell

      Vertex Adult Cystic Fibrosis Research Award: Sandra Hodge, Peter Zalewski, David Parsons, Andrew Tai, Sally Chapman, Judith Morton, and Emily Hopkins

      Vertex Paediatric Cystic Fibrosis Research Award: Shafagh Waters and Adam Jaffe

      Maurice Blackburn Grant-in-Aid for Occupational Lung Disease: Mariane T Turner, Samuel Sameh, Robert A Cohen, and Deborah H Yates           

      TSANZ Rob Pierce Grant-In-Aid for Indigenous Lung Health: Kristin Carson-Chahhoud

      TSANZ Peter Phelan Paediatric Research Award: Shivanthan Shanthikumar

      TSANZ / Boehringer Ingelheim Australia COPD Travel Award: Katrina Tonga

      TSANZ / Boehringer Ingelheim New Zealand COPD Travel Award: Hajar Ali

      TSANZ/JRS Early Career Development Award: Saleela Ruwanpura

      Janet Elder International Mid-Career Travel Award: David G Chapman

      Janet Elder International Early Career Travel Award Recipient 1: Steven Taylor

      Janet Elder International Early Career Travel Award Recipient 2: Tony Zhang

      TSANZ Respiratory Nurses Career Development Award for Indigenous Research:Kobi Schutz

       

      TSANZ would like to thank our partners and sponsors for their support of excellent respiratory research and researchers!

      2020 TSANZ Awards by Nomination

      At TSANZ 2020 AGM we recognised seven leaders in their field of lung health.

      TSANZ 50th Anniversary Medal for Education and Training – Associate Professor David Fielding.

      The 50th Anniversary Medal is awarded each year in recognition of outstanding contributions to respiratory education and training in Australia or New Zealand.

      TSANZ Research Medal – Professor Shyamali Dharmage, Professor Alan James

      This award acknowledges the recipient’s outstanding contribution to the advancement of the practice of thoracic medicine in Australia and New Zealand. This year, due to the calibre of nominations, the TSANZ Board has chosen two recipients for the TSANZ Research Medal.

      TSANZ Society Medal – Associate Professor Tara Mackenzie

      This award acknowledges the recipient’s outstanding contribution to the advancement of the practice of thoracic medicine in Australia and New Zealand.

      Fellowships

      • Professor Richard Beasley
      • Professor Margaret Wilsher
      • Professor Ross Vlahos

      Each year the TSANZ board considers peer nominations for Fellow status of the Thoracic Society of Australia and New Zealand (TSANZ). Fellow status is awarded to members who have demonstrated exceptional contributions to the field of respiratory health in Australia or New Zealand.

      Congratulations to all!

      Respirology – Editor’s Choice 

      Respirology Issue 25.5 May 2020

       

      Artificial stone-associated silicosis in China: A prospective comparison with natural stone-associated silicosis

      Na Wu, Changjiang Xue, Shiwen Yu and Qiao Ye

       

      Chest HRCT of 2 peatients with natural stone-associated findings (top) and 2 patients with artificial stone-associated silicosis (Bottom)

      DOI: 10.1111/resp.13744

       

      Acute exacerbations of fibrotic interstitial lung diseases

      Atsushi Suzuki, Yasuhiro Kondoh, Kevin K. Brown, Takeshi Johkoh, Kensuke Kataoka, Junya Fukuoka, Tomoki Kimura, Toshiaki Matsuda, Toshiki Yokoyama, Jun Fukihara, Masahiko Ando, Tomonori Tanaka, Naozumi Hashimoto, Koji Sakamoto and Yoshinori Hasegawa

       

      Researchers from the ILD collaborative team from Japan and US. From left to right: (front) Dr. Yasuhiro Kondoh, Dr. Kevin K. Brown, Dr. Yoshinori Hasegawa; (back) Dr. Atsushi Suzuki, Dr. Koji Sakamoto, Dr. Naozumi Hashimoto, Dr. Kensuke Kataoka, Dr. Yuji Saito.

      DOI: 10.1111/resp.13682

      Respirology Issue 25.6 June 2020

       

      Effects of E-cigarette E-liquid components on bronchial epithelial cells: Demonstration of dysfunctional efferocytosis

      Miranda P. Ween, Rhys Hamon, Matthew G, Macowan, Leigh Thredgold, Paul R. Reynolds and Sandra J. Hodge

       

      A collection of e-cigarettes and e-liquids for sale to vapers

      DOI: 10.1111/resp.13696

       

      Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF

      Erica Farrand, Eric Vittinghoff, Brett Ley, Atul J. Butte and Harold R. Collard

       

       

      The research team from the University of California San Francisco in the United States (c269928 represents Brett Ley)

      DOI: 10.1111/resp.13753

      TSANZSRS 2020 Abstracts

      Due to the COVID-19 pandemic, the TSANZSRS 2020 ASM has been postponed until 30 April – 4 May 2021. This supplement contains Abstracts that were accepted for presentation at the 2020 meeting.

      Volume 25, Issue S1 TSANZSRS 2020 The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science, 27–31 March 202

       

      Invitations and surveys

       

      CYSTIC FIBROSIS RESEARCH AND ADVOCACY PRIORITY SETTING SURVEY 2020 AND BEYOND

      Dear Members of the Thoracic Society of Australia and New Zealand,

      Cystic Fibrosis Australia (CFA) is inviting the TSANZ members to take part in their Research and Advocacy Priority Setting survey. If you are a CF stakeholder, living with the condition or looking after someone who lives with the condition, then your survey responses are greatly needed and encouraged.

      https://www.surveymonkey.com/r/F38Q8K2

      We want all our community members, patients, carers, clinicians and researchers to be involved in every step and we thank you for agreeing to take part.

      To speak to us about this questionnaire or for any further enquires, contact us at (02) 9889 5171 or email nickim@cfa.org.au. Alternatively, you can join the conversation over at the Cystic Fibrosis Australia page on Facebook.

       

      INVITATION TO PARTICIPATE IN AN ERS STUDY AIMING TO IMPROVE THE QUALITY OF CLINICAL TRIALS EVALUATING THE MANAGEMENT OF COPD EXACERBATIONS

      Dear colleagues,

      Clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations evaluate heterogeneous outcomes (endpoints), often omitting those that are clinically important and relevant to patients. This limits their usability and comparability.

      To remedy this issue, the European Respiratory Society (ERS) set-up a Task Force aiming to develop a core outcome set (COS). A COS is a consensus-based minimum set of clinically important outcomes that should be evaluated in all future clinical trials on the management of COPD exacerbations.

      We have identified around 50 outcomes of COPD exacerbations and we need your help to prioritize a small number of the most important outcomes, to be included in the core outcome set and to be evaluated in all future clinical trials on the management of COPD exacerbations. To help us prioritize the outcomes, we will be grateful if you could complete a survey that has two stages, 4-8 weeks apart. Each survey takes about 20 minutes to complete.

      In the first survey, you will be asked to rate the importance of 50 outcomes between 1-9:

      • 1-3: Outcomes of limited importance.
      • 4-6: Outcomes that are important but not critical.
      • 7-9: Critical outcomes.

      We welcome responses from health professionals, researchers, patients with COPD and any other stakeholders with interest in COPD exacerbations.

      In the second survey, you will see a graph summarizing the responses of all participants in the first survey and you will be asked to reconsider your ratings, taking into consideration the views of the other responders. While the aim of this survey will be to reach consensus, you will not have to change your ratings if you do not want to.

      Your opinion in both surveys is extremely important in developing the core outcome set.

      It is crucial that you complete both surveys and we would be very grateful if you can do this.

      Please, take the survey in one of the following languages:

      English: https://delphimanager.liv.ac.uk/COPD/
      Portuguese: https://delphimanager.liv.ac.uk/COPD-PO/
      German: https://delphimanager.liv.ac.uk/COPD-GE/
      Hungarian:  https://delphimanager.liv.ac.uk/COPD-HU/
      Mandarin: https://delphimanager.liv.ac.uk/COPD-CN/
      Spanish: https://delphimanager.liv.ac.uk/COPD-ES/
      Russian: https://delphimanager.liv.ac.uk/COPD-RU/
      Greek: https://delphimanager.liv.ac.uk/COPD-GR/
      Danish: https://delphimanager.liv.ac.uk/COPD-DK/
      Italian: https://delphimanager.liv.ac.uk/COPD-IT/

      We appreciate this is a difficult time for patients and professionals in the respiratory community. While all efforts should rightly be focused on caring for those affected by the novel coronavirus and COVID-19, we believe that research to improve care and outcomes for respiratory patients is needed now more than ever. We are sensitive to the enormous pressures faced by patients and professionals in our community and will review the timelines for this survey and subsequent work in response to the ongoing global pandemic.

      Thank you very much in advance,
      Kind regards,
      Associate Prof. Jens-Ulrik Jensen,
      Dr. Alexander Mathioudakis,
      Prof. Jørgen Vestbo,
      On behalf of the study team.

       

      NURSES’ ATTITUDES TO CARING FOR PEOPLE WITH INTELLECTUAL DISABILITY: AN AUSTRALIAN SURVEY

      Dear Colleagues,

      We invite you to consider participating in our online survey focused on nurses’ attitudes to caring for people with intellectual disability. This survey, led by researchers from Western Sydney and Central Queensland Universities, is a replication of a previous US study by Dr Melissa Desroches from the University of Massachusetts, Dartmouth.

      People with intellectual disability have lower levels of general health than other members of our community. They also have higher incidence of hospitalisation and, of major concern, higher incidence of preventable death than members of the general population.

      By learning about nurses’ attitudes to caring for people with intellectual disability, we anticipate being able to develop models of care and supportive resources for nurses to enhance the care that they provide to people with intellectual disability.

      Please read the attached participant information sheet and consider completing this short survey by accessing the link below:

      Caring for People with Intellectual Disability survey

      Thank you for considering our invitation
      A/Prof Nathan Wilson, Western Sydney University
      Dr Peter Lewis, Western Sydney University
      Ms Virginia Howie, Central Queensland University
      Dr Melissa Desroches, University of Massachusetts, Dartmouth

      Kind regards,
      Virginia

       

      GLOBAL CURRENT PRACTICES OF MECHANICAL VENTILATION MANAGEMENT IN COVID-19 PATIENTS

      Dear Colleague, 

      You are invited to partake in the current study, “Global Current Practices of Mechanical Ventilation Management in COVID-19 Patients.” The goal of this study is to explore the current practices of mechanical ventilation support in adult COVID-19 patients worldwide. 

      We are carrying out this online survey for frontline clinicians involved in the care of patients with COVID-19, with the aim to examine which ventilation techniques healthcare providers’ used to manage adult COVID-19 patients. It would be helpful if you could complete this survey, the estimated time is 5-10 minutes. While there is limited information available on ventilatory support practices in COVID-19 patients, this international survey will provide further insights into current strengths and limitations of global practices.

      Rest assured that your answers will be kept confidential, and no information will be used to identify you or your response. This research project was approved by the Institutional Review Board (IRB), AFHER-IRB-2020-012.

      If you have any concern or question regarding this study, please do not hesitate to contact me at Jaber.alqahtani.18@ucl.ac.uk.

      THANK YOU!
      Jaber Alqahtani
      On behalf of the whole international team

       

      INVITATION TO PARTICIPATE IN A STUDY ON SELF MANAGEMENT FOR PULMONARY FIBROSIS: WHAT DOES IT MEAN AND HOW MIGHT IT HELP?

      Dear Members of the Thoracic Society of Australia and New Zealand, 

      Alfred Health and the Centre of Research Excellence in Pulmonary Fibrosis are inviting health professionals involved with pulmonary fibrosis (PF) to take part in a study on self-management for pulmonary fibrosis: what does it mean and how might it help? 

      Participation is voluntary and involves you sharing your views, opinions and experiences on the patients’ management of PF through a confidential telephone interview of about 30 minutes in duration

      Your perspective is important to help us identify and develop resources that will provide patients with the knowledge and tools to manage their own wellbeing. In turn, this will help health professionals to be better equipped to provide support to people with PF and their families. 

      The study has been approved by the Alfred Health Human Ethics Committee (Project number: 144/20). 

      If you are interested in participating or would like further information on this study, please contact: 

      Professor Anne Holland (Chief Investigator) 
      Professor of Physiotherapy, 
      Monash University and Alfred Health 
      Email: Anne.Holland@monash.edu 
      Telephone: (03) 9903 0214 

      Ms Joanna Lee (PhD candidate)
      Monash University and Alfred Health
      Email: joanna.lee2@monash.edu
      Mobile: 0431 689 361

      Thank you for your time and consideration of our study. 

       

      IDENTIFYING BARRIERS AND FACILITATORS TO THE IMPLEMENTATION OF BEST PRACTICE FOR PULMONARY FIBROSIS IN AUSTRALIA

      What are the barriers and facilitators to implementing best practice?

      Dear Members of the Thoracic Society of Australia and New Zealand,

      The Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is inviting physicians involved in the management of people with pulmonary fibrosis (PF) to take part in our study aimed at identifying the barriers and facilitators to the implementation of best practice for the diagnosis, treatment and management of the disease.

      Participation is voluntary and involves providing your views, opinions and experiences on the management of PF through confidential, in person interviews of about 30 minutes in duration. 

      Your perspective is important to help us understand the barriers that may be impeding the implementation of best practice in clinical settings. The findings have the potential to guide the development of behaviour change strategies aimed at improving implementation and in turn, optimise the prognosis and management pathways for people with this insidious disease.

      Like more information or interested in participating? Click here

      The study has been approved by the Monash University Human Ethics Committee (Number 22350) and the Sydney Local Health District Human Ethics Committee (Number 2019/ETH13556).

      If you would like to speak to us about any aspect of this study, please contact:

      Professor Anne Holland
      Professor of Physiotherapy, Monash University and Alfred Health
      Department of Allergy, Clinical Immunology and Respiratory Medicine, Monash University
      Anne.Holland@monash.edu or (03) 9903 0214

      Thank you for your time and consideration of our study.

      ASCOT trial

      ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

      The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand and Asia. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

      Potential Treatments for COVID-19

      There are currently no specific therapies for COVID-19. The two main strategies are to limit the virus replicating (antiviral therapies) or to modulate the immune response (in some severe cases, there is a damaging over exuberant immune response).

      ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

      ASCOT Trial Intervention

      Initially, an open label trial of two existing treatments in a 2×2 factorial design with usual care arm will be conducted.

      1. Lopinavir/ritonavir (kaletra), a combination medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection
      1. Hydroxychloroquine, a medicine used to treat rheumatoid arthritis and other inflammatory conditions and to prevent and treat malaria.

       

      Protocol documents and further details are available at www.ascot-trial.edu.au

       

      Can you help TSANZ make a difference?
       

      Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

      1. Making a donation to our Benevolent Fund

      The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
      CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      2. Making a donation to support research

      With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
      Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      3. Establishing a named award

      For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

      4. Leave TSANZ a gift in your will

      If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
      If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

      5. TSANZ New Zealand Branch Incorporated 

      New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt. 
      CLICK HERE to make a donation.

      Thank you for your continued support of TSANZ.

       

      .

       

      VOLUME 6.05 – JULY 2021

      VOLUME 5.03 – APRIL 2020

      Research Roundup:

      April 2020

      .

      Welcome Message

      Welcome to another edition of our TSANZ Research Roundup. We currently have two invitations on offer – one for a study in Identifying barriers and facilitators to the implementation of best practice for pulmonary fibrosis in Australia, the other for participation in the ASCOT trial.

      Submissions are always open for our “Research Roundup Holy Grail,” supported by the limbic. You will be featured in an upcoming Research Roundup and also published on the limbic website. This is a great opportunity to tell us about your research and inspiration, and provides a platform to be able to connect your passion project with our network of TSANZ members and the limbic subscribers. Details can be found here.

      Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

      Enjoy the March edition of your Research Roundup.

      Prof Sandra Hodge

      Chair, Research Sub-Committee

      Respirology – Editor’s Choice 

      Respirology Issue 25.4 April 2020

       

      We won’t find what we don’t look for: Identifying barriers and enablers of chronic wet cough in Aboriginal children

      Pamela Laird, Roz Walker, Mary Lane, Anne B. Chang and Andre Schultz

       

      DOI: 10.1111/resp.13642

       

      Obesity hypoventilation syndrome treated with non-invasive ventilation: Is a switch to CPAP therapy feasible?

      Maria P. Arellano-Maric, Christine Hamm, Marieke L. Duiverman, Sarah Schwarz, Jens Callegari, Jan H. Storre, Claudia Schmoor, Marc Spielsmanns, Wolfgang Galetke and Wolfram Windisch

       

      Principal investigator Maria Paola Arellano-Maric, MD (left) and senior investigator Prof. Dr. Wolfram Windisch (right)

      DOI: 10.1111/resp.13704

      ASCOT Trial

      ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

      The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand and Asia. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

      Potential Treatments for COVID-19

      There are currently no specific therapies for COVID-19. The two main strategies are to limit the virus replicating (antiviral therapies) or to modulate the immune response (in some severe cases, there is a damaging over exuberant immune response).

      ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

      ASCOT Trial Intervention

      Initially, an open label trial of two existing treatments in a 2×2 factorial design with usual care arm will be conducted.

      1. Lopinavir/ritonavir (kaletra), a combination medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection
      1. Hydroxychloroquine, a medicine used to treat rheumatoid arthritis and other inflammatory conditions and to prevent and treat malaria.

       

      Protocol documents and further details are available at www.ascot-trial.edu.au

      Invitation

      IDENTIFYING BARRIERS AND FACILITATORS TO THE IMPLEMENTATION OF BEST PRACTICE FOR PULMONARY FIBROSIS IN AUSTRALIA

      What are the barriers and facilitators to implementing best practice?

      Dear Members of the Thoracic Society of Australia and New Zealand,

      The Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is inviting physicians involved in the management of people with pulmonary fibrosis (PF) to take part in our study aimed at identifying the barriers and facilitators to the implementation of best practice for the diagnosis, treatment and management of the disease.

      Participation is voluntary and involves providing your views, opinions and experiences on the management of PF through confidential, in person interviews of about 30 minutes in duration. 

      Your perspective is important to help us understand the barriers that may be impeding the implementation of best practice in clinical settings. The findings have the potential to guide the development of behaviour change strategies aimed at improving implementation and in turn, optimise the prognosis and management pathways for people with this insidious disease.

      Like more information or interested in participating? Click here

      The study has been approved by the Monash University Human Ethics Committee (Number 22350) and the Sydney Local Health District Human Ethics Committee (Number 2019/ETH13556).

      If you would like to speak to us about any aspect of this study, please contact:

      Professor Anne Holland

      Professor of Physiotherapy, Monash University and Alfred Health

      Department of Allergy, Clinical Immunology and Respiratory Medicine, Monash University

      Anne.Holland@monash.edu or (03) 9903 0214

      Thank you for your time and consideration of our study.

       

      Can you help TSANZ make a difference?
       

      Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

      1. Making a donation to our Benevolent Fund

      The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
      CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      2. Making a donation to support research

      With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
      Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      3. Establishing a named award

      For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

      4. Leave TSANZ a gift in your will

      If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
      If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

      5. TSANZ New Zealand Branch Incorporated 

      New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt. 
      CLICK HERE to make a donation.

      Thank you for your continued support of TSANZ.

      VOLUME 6.05 – JULY 2021

      VOLUME 5.02 – MARCH 2020

      Research Roundup:

      March 2020

      .

      Welcome Message

      By now I’m sure you’ve heard that TSANZSRS 2020 has been postponed until 29 April – 4 May 2021. The TSANZ Board released a letter and FAQ outlining this decision on 12 March 2020.

      The Board is busy working through all the issues that have arisen from this decision and we will be in touch with updates as they happen. Whilst the the Research Sub-Committee has finalised most awards, we are now looking at how to publicly acknowledge 2020 award recipients. 

      COVID-19

      Infectious diseases research is a significant area of strength in Australia and the TSANZ acknowledges the important work of our Australian researchers who are international leaders in research surrounding COVID-19. Examples include the creation of the vaccine candidate for COVID-19 by the University of Queensland – achieved in just three weeks! Scientists at CSIRO’s state-of-the-art biologics production facility in Melbourne have already begun small-scale testing. Doherty Institute researchers have mapped immune responses from one of Australia’s first novel coronavirus (COVID-19) patients, showing the body’s ability to fight the virus and recover from the infection (published in Nature) while CSIRO’s research aims to get a better understanding of the virus – how long it takes to develop and replicate, how it impacts the respiratory system and how it can be transmitted. 

      We also acknowledge the support of the Australian Government that will invest $30 million for COVID-19 research to enable Australian researchers to contribute to global efforts to control the outbreak. In addition, NHMRC recognises that the COVID-19 pandemic may be affecting the research of current grant holders. If you have received a grant and circumstances have changed – for example, there has been a delay in your Research Activity because of involvement in the clinical or public health response – you can apply to vary your grant. Variations that may be relevant due to the impact of COVID-19 include: Deferral of commencement date and requests for grants applications, deferral of an in-progress grant and extended leave requests, extended end date, change to a research plan or change to chief investigators. For more information please visit: https://www.nhmrc.gov.au/funding/manage-your-funding/vary-your-grant.

      TSANZ are collaborating to support the Australian Living Evidence Consortium who, with Cochrane Australia are working to develop a National COVID-19 Clinical Evidence Taskforce. There is a survey below which will help to determine high-priority clinical questions and a request for EOIs to join the guideline panel. I encourage all interested parties to contribute to this work through the article below.

      We wish you all the best in your work and in preparation of your grant applications.

      Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

      Enjoy the March edition of your Research Roundup.

      Prof Sandra Hodge

      Chair, Research Sub-Committee

      National COVID-19 Clinical Evidence Taskforce

      Dear colleague,

      The Australian Living Evidence Consortium and Cochrane Australia are working with others to support the development of a National COVID-19 Clinical Evidence Taskforce. As part of this we are working with peak professional bodies to develop living, evidence-informed guidance for primary, hospital and critical care of adults and children with suspected or confirmed COVID-19 infection. Guidance will be updated weekly as new evidence emerges.

      We would like your suggestions for high-priority clinical questions to be addressed by this guidance.

      Please suggest questions by completing the form at https://forms.gle/SDS9t2tMhiHvnRoPA by 9pm Sunday March 22.

      We are also seeking interested clinicians to join guideline panels. These will initially be convened next week, and then meet regularly over the next weeks and months to review emerging evidence and refine the recommendations. To express your interest in membership in a guideline panel, please email your CV to Dr Britta Tendal, Senior Research Fellow at Cochrane Australia at britta.tendal@monash.edu by 9pm Sunday March 22. 

      If you have any queries please contact Dr Tari Turner, Senior Research Fellow at Cochrane Australia at tari.turner@monash.edu

      Thank you

      Respirology – Editor’s Choice 

      Respirology Issue 25.3 March 2020

       

      Global Lung Function Initiative‐2012 ‘other/mixed’ spirometry reference equation provides the best overall fit for Australian Aboriginal and/or Torres Strait Islander children and young adults

      Tamara L. Blake, Anne B. Chang, Mark D. Chatfield, Julie M. Marchant and Margaret S. McElrea

       

      DOI: 10.1111/resp.13649

      Study participant from Thursday Island performing spirometry (with permission by the Queensland Government)

       

      Association of serious adverse events with Cheyne–Stokes respiration characteristics in patients with systolic heart failure and central sleep apnoea: A SERVE-Heart Failure substudy analysis

      Faizan Javed, Renaud Tamisier, Jean-Louis Pepin, Martin R. Cowie, Karl Wegscheider, Christiane Angermann, Marie-Pia D’ortho, Erland Erdmann, Anita K. Simonds, Virend K. Somers, Helmut Teschler, Patrick Levy, Jeff Armitstead and Holger Woehrle

       

       Schematic representation of CheyneStokes respiration signal.

      DOI: 10.1111/resp.13613

      Invitation

      IDENTIFYING BARRIERS AND FACILITATORS TO THE IMPLEMENTATION OF BEST PRACTICE FOR PULMONARY FIBROSIS IN AUSTRALIA

      What are the barriers and facilitators to implementing best practice?

      Dear Members of the Thoracic Society of Australia and New Zealand,

      The Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is inviting physicians involved in the management of people with pulmonary fibrosis (PF) to take part in our study aimed at identifying the barriers and facilitators to the implementation of best practice for the diagnosis, treatment and management of the disease.

      Participation is voluntary and involves providing your views, opinions and experiences on the management of PF through confidential, in person interviews of about 30 minutes in duration. 

      Your perspective is important to help us understand the barriers that may be impeding the implementation of best practice in clinical settings. The findings have the potential to guide the development of behaviour change strategies aimed at improving implementation and in turn, optimise the prognosis and management pathways for people with this insidious disease.

      Like more information or interested in participating? Click here

      The study has been approved by the Monash University Human Ethics Committee (Number 22350) and the Sydney Local Health District Human Ethics Committee (Number 2019/ETH13556).

      If you would like to speak to us about any aspect of this study, please contact:

      Professor Anne Holland

      Professor of Physiotherapy, Monash University and Alfred Health

      Department of Allergy, Clinical Immunology and Respiratory Medicine, Monash University

      Anne.Holland@monash.edu or (03) 9903 0214

      Thank you for your time and consideration of our study.

       

      Can you help TSANZ make a difference?
       

      Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

      1. Making a donation to our Benevolent Fund

      The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
      CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      2. Making a donation to support research

      With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
      Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

      3. Establishing a named award

      For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

      4. Leave TSANZ a gift in your will

      If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
      If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

      5. TSANZ New Zealand Branch Incorporated 

      New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt. 
      CLICK HERE to make a donation.

      Thank you for your continued support of TSANZ

      WHY JOIN US?

      Become part of a network of professionals working in respiratory and lung health clinical care and treatment, research, health promotion and advocacy.

      By browsing our website you agree to our use of cookies outlined in our revised Privacy Policy and Terms & Conditions.

      X